Pfizer (NYSE:PFE) Updates FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus earnings per share estimate of 2.970. The company issued revenue guidance of $60.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.7 billion.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Finally, Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Trading Down 0.2%

NYSE:PFE traded down $0.06 during trading hours on Tuesday, hitting $24.97. The stock had a trading volume of 7,889,126 shares, compared to its average volume of 41,999,121. The business’s 50 day moving average is $25.03 and its 200-day moving average is $26.16. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market cap of $142.32 billion, a price-to-earnings ratio of 19.07 and a beta of 0.34. Pfizer has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm posted $0.78 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is currently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer posted adjusted earnings per share of $0.77, above the $0.68 consensus estimate, while revenue rose 2.6% year over year to $15.03 billion versus expectations of $14.40 billion. Pfizer second-quarter press release
• Positive Sentiment: Growth in non-COVID products, particularly the blood thinner Eliquis and oncology medicines, drove the quarterly beat and helped offset weakening COVID-19 product demand. Reuters Eliquis earnings article
• Positive Sentiment: Pfizer raised its 2026 revenue outlook to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, increasing the midpoint by $500 million. Management reaffirmed adjusted EPS guidance of $2.80-$3.00 despite an estimated $0.10 impact from its Innovent Biologics transaction. CNBC Pfizer earnings article
• Neutral Sentiment: The results reinforce Pfizer’s strategy of replacing pandemic-related revenue with oncology and other newer products, but investors will likely look for evidence that these businesses can sustain growth as COVID sales continue to shrink. Pfizer second-quarter results announcement
• Negative Sentiment: Pfizer swung to a second-quarter reported loss despite higher revenue. The modest guidance improvement may have fallen short of investor hopes following the earnings beat, contributing to weakness in the shares. Wall Street Journal Pfizer loss article

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently modified their holdings of PFE. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank grew its stake in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its holdings in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.